Immunai

Immunai is a multidisciplinary biotech company on a mission to fully map the immune system to revolutionize drug discovery and development. Central to its efforts is AMICA, a comprehensive single-cell immune data foundation built through organic development and two key acquisitions: Dropprint Genomics (March 2021), a Y Combinator-backed single-cell genomics software company, and Nebion (July 2021), a world leader in biocuration and data integration. Using single-cell multiomics and machine learning, Immunai builds high-resolution profiles of immune cells to predict patient responses to treatments and identify novel therapeutic targets for oncology and inflammatory diseases. The company works with leading academic centers and biopharmaceutical partners including AstraZeneca and Teva. Founded in December 2018 by CEO Noam Solomon, PhD, Immunai is headquartered in New York City with offices in Tel Aviv, Prague, and Zurich, and a team of 80+ PhDs across immunology, engineering, drug development, computer science, and entrepreneurship.